| Drugs | Manic or mixed episodes | Depressive episodes | Maintenance treatment | Remarks | Adverse reactions |
| Lithium | | | | Anti-suicidal effect | Hypothyroidism, elevated calcium levels, decreased kidney function |
| Carbamazepine extended release | | | | / | CYP450-inducing effects, hepatotoxicity, granulocyte deficiency, rash, teratogenic effects |
| Valproic acid extended release | | | | Effective for mixed state treatment | CYP450 inhibition, teratogenic effects, hepatotoxicity, tremor, thrombocytopenia |
| Lamotrigine | | | | Helps prevent depressive episodes; requires slow dose increases | Skin rash, Stevens-Johnson syndrome |
| Aripiprazole | | | | Favorable metabolism in patients with predominantly manic | Inability to sit still |
| Asenapine | | | | Effective for depressive symptoms | Inability to sit still, drowsiness, risk of metabolic syndrome |
| Calirazin | | | | Good metabolism | Inability to sit still |
| Chlorpromazine | | | | Fast-acting | Risk of turning depressed, sedation, extrapyramidal symptoms |
| Lurasidone | | | | Good metabolism when taken with food | Inability to sit still and sedation |
| Olanzapine | | | | Fast acting | Drowsiness, high risk of metabolic abnormalities |
| Auflur Combination | | | | / | Drowsiness, high risk of metabolic abnormalities |
| Quetiapine immediate release | | | | Effective prevention of mania and depression | Drowsiness, weight gain, metabolic abnormalities |
| Quetiapine extended release | | | | Effective prevention of mania and depression | Drowsiness, weight gain, metabolic abnormalities |
| Risperidone | | | | Monthly intramuscular dosage form for maintenance therapy | Extrapyramidal side effects, weight gain, metabolic abnormalities, hyperlactatemia |
| Ziprasidone | | | | Favorable metabolism in patients with predominantly manic | Prolonged QTC interval, inability to sit still, hypotension |